1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair

 
• By Jessica Merrill

Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.

AirDuo RespiClick inhalers

Teva Pharmaceutical Industries Ltd. has taken the interesting step of launching AirDuo RespiClick (fluticasone/salmeterol) and an aggressively discounted authorized generic in the US on the same day. The company announced the availability of the two products April 20, both of which are formulated with the same active ingredients as GlaxoSmithKline PLC's AdvairDiskus, but are administered through a different device.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Paratek To Acquire Optinose, Expanding Portfolio Beyond Antibiotics

 
• By Joseph Haas

Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.

More from Therapy Areas

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.